AlphaYou
Overview
Smart money at a glance
Filings to Oct 5, 2026Net selling: insiders sold $259K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$259K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Mar 31, 2026
- 0 added, 1 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- Open
- $5.73
- 52-wk high
- $8.00
- High
- $5.87
- 52-wk low
- $4.33
- Low
- $5.61
- Prev close
- $5.73
- Mkt cap
- $2.17B
- Volume
- 3.28M
- Fwd P/E
- 1.3x
- Beta
- 0.37
- P/S
- 0.2x
- P/B
- 18.8x
- Profit margin
- -10.1%
- Op margin
- +27.2%
- ROE
- +43.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about BHC filings
Are insiders buying or selling Bausch Health Companies Inc (BHC) stock?
Net selling: insiders sold $259K and bought $0 of BHC stock on the open market in the 90 days to Oct 5, 2026, according to SEC Form 4 filings. $259K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Lenar, Aimee J. (President, US Pharma), who sold $259K. The latest filing was on Aug 20, 2026.
Which members of Congress have traded BHC recently?
None. No member of Congress disclosed a BHC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this BHC smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (1)
- BO
Bank of America
$7.3M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in BHC right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 31.3% above what analysts expected.
Last report
Jul 29, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.96 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | $1.26 / $0.96Alpha Vantage | +31.25% beat | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 29, 2026 | $0.78 / $0.69Alpha Vantage | +13.04% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 18, 2026 | $1.08 / $1.21Alpha Vantage | -10.74% miss | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 29, 2025 | $1.16 / $1.06Alpha Vantage | +9.43% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 30, 2025 | $0.91 / $0.94Alpha Vantage | -3.19% miss | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 30, 2025 | $0.61 / $0.85Alpha Vantage | -28.24% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 19, 2025 | $1.16 / $1.13Alpha Vantage | +2.96% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $1.13 / $1.02Alpha Vantage | +10.78% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 4, 2026, in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.68B | $2.80B | $2.52B | $2.85B |
| Cost of what it sold | $750.0M | $798.0M | $738.0M | $772.0M |
| Gross profit | $1.93B | $2.00B | $1.79B | $2.08B |
| What it spent | ||||
| Research and development | $247.0M | $51.0M | $163.0M | $173.0M |
| Sales and admin | $795.0M | $882.0M | $861.0M | $907.0M |
| Other operating costs | $253.0M | $236.0M | $241.0M | $225.0M |
| Total operating expenses | $1.29B | $1.17B | $1.26B | $1.30B |
| What was left | ||||
| Operating profit | $636.0M | $829.0M | $521.0M | $775.0M |
| Interest on debt | $412.0M | $397.0M | $402.0M | $396.0M |
| Profit before tax | $218.0M | $56.0M | -$1.35B | $348.0M |
| Tax | $37.0M | $159.0M | $77.0M | $88.0M |
| Net profit | $179.0M | -$112.0M | -$1.42B | $258.0M |
| EBITDA | $936.0M | $743.0M | -$657.0M | $1.02B |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace